Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHA:688076)
China · Delayed Price · Currency is CNY 29.76
+0.41 (1.40%)
Sep 30, 2026, 3:00 PM CST
SHA:688076 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 9,406 | 11,915 | 11,411 | 9,583 | 4,890 | 8,811 | |
Market Cap Growth | -27.94% | 4.42% | 19.08% | 95.95% | -44.50% | - |
Enterprise Value | 11,292 | 13,443 | 12,107 | 9,772 | 4,726 | 8,238 |
Last Close Price | 29.76 | 37.22 | 36.09 | 30.99 | 15.73 | 28.18 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 39.50 | 35.84 | 28.22 | 58.81 | 37.88 | 76.36 |
Forward PE | - | 17.44 | 20.25 | 50.65 | 31.86 | 42.28 |
PS Ratio | 4.62 | 6.13 | 7.02 | 9.27 | 7.51 | 13.68 |
PB Ratio | 3.03 | 3.97 | 4.26 | 4.38 | 2.54 | 4.87 |
P/TBV Ratio | 3.44 | 4.46 | 4.77 | 5.04 | 2.95 | 5.64 |
P/OCF Ratio | 13.93 | 17.49 | 28.52 | 27.36 | 166.95 | 48.75 |
PEG Ratio | - | 1.03 | - | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 5.55 | 6.92 | 7.45 | 9.46 | 7.26 | 12.79 |
EV/EBITDA Ratio | 13.82 | 17.57 | 18.25 | 30.27 | 27.72 | 41.45 |
EV/EBIT Ratio | 25.45 | 28.97 | 26.27 | 51.15 | 65.84 | 70.35 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.91 | 0.89 | 0.61 | 0.41 | 0.17 | 0.05 |
Debt / EBITDA Ratio | 3.47 | 3.41 | 2.45 | 2.74 | 1.86 | 0.41 |
Net Debt / Equity Ratio | 0.61 | 0.54 | 0.32 | 0.07 | -0.06 | -0.33 |
Net Debt / EBITDA Ratio | 2.34 | 2.13 | 1.30 | 0.45 | -0.72 | -3.00 |
Net Debt / FCF Ratio | -4.86 | -2.38 | -1.25 | -0.47 | 0.30 | 11.32 |
Asset Turnover | 0.31 | 0.33 | 0.38 | 0.34 | 0.28 | 0.37 |
Inventory Turnover | 1.16 | 1.12 | 1.20 | 1.27 | 1.07 | 1.41 |
Quick Ratio | 0.72 | 0.75 | 0.79 | 1.08 | 1.26 | 2.99 |
Current Ratio | 1.14 | 1.16 | 1.14 | 1.54 | 1.91 | 4.01 |
Return on Equity (ROE) | 7.66% | 11.46% | 16.43% | 8.04% | 6.58% | 7.84% |
Return on Assets (ROA) | 4.28% | 4.91% | 6.68% | 3.93% | 1.93% | 4.15% |
Return on Invested Capital (ROIC) | 8.05% | 10.25% | 14.30% | 8.82% | 4.75% | 8.90% |
Return on Capital Employed (ROCE) | 9.30% | 10.10% | 13.90% | 7.40% | 3.60% | 6.30% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 2.52% | 2.79% | 3.54% | 1.70% | 2.64% | 1.31% |
FCF Yield | -4.10% | -5.75% | -6.05% | -3.24% | -8.37% | -0.60% |
Dividend Yield | 1.18% | 0.94% | 1.78% | 0.92% | 0.91% | 0.38% |
Payout Ratio | 77.60% | 72.08% | 29.37% | 35.36% | 31.43% | 5.24% |
Buyback Yield / Dilution | -1.76% | -1.59% | -2.86% | -1.28% | -10.06% | -19.95% |
Total Shareholder Return | -0.58% | -0.65% | -1.07% | -0.36% | -9.16% | -19.57% |